Content about Reproductive system

April 1, 2013

The Food and Drug Administration has approved a new contraceptive therapy made by Teva Pharmaceutical Industries, Teva said Monday.

JERUSALEM — The Food and Drug Administration has approved a new contraceptive therapy made by Teva Pharmaceutical Industries, Teva said Monday.

The drug maker announced the approval of Quartette (levonorgestrel, ethinyl estradiol and ethinyl estradiol) tablets. Teva said the drug represented the "next generation" of extended-regimen oral contraceptives and was designed to minimize breakthrough bleeding between scheduled periods.

February 26, 2013

FDA approves drug for pain during sex due to menopause

The Food and Drug Administration has approved a drug for postmenopausal women who experience pain during sex.

SILVER SPRING, Md. — The Food and Drug Administration has approved a drug for postmenopausal women who experience pain during sex.

The agency announced the approval of Shionogi's Osphena (ospemifene) for women with moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause associated with declining levels of estrogen hormones.

November 28, 2012

Biocom develops alternative to sanitary napkins, tampons

Regional life sciences association Biocom has introduced a new eco-friendly alternative to sanitary napkins and tampons. Enter FemmyCycle, a product from member FemCap.

SAN DIEGO — Regional life sciences association Biocom has introduced a new eco-friendly alternative to sanitary napkins and tampons. Enter FemmyCycle, a product from member FemCap.

The FemmyCycle was granted clearance by the U.S. Food and Drug Administration on Nov. 16. FemmyCycle creator Alfred Shihata is familiar with developing feminine products. His FDA-approved FemCap is one of the few hormone-free, woman-controlled contraceptive methods available.

November 7, 2012

Absorption Pharmaceuticals launches men's intimacy health solution

Absorption Pharmaceuticals recently launched Promescent, an over-the-counter lidocaine-based spray indicated for premature ejaculation.

NEWPORT BEACH, Calif. — Absorption Pharmaceuticals recently launched Promescent, an over-the-counter lidocaine-based spray indicated for premature ejaculation. The product is presently available at www.Promescent.com, through doctors’ offices and independent pharmacies.

Created by a urologist, the spray is designed to absorb below the surface of the skin where nerve endings that control ejaculation are located.

August 13, 2012

FDA accepts Teva contraceptive pill application

The Food and Drug Administration is reviewing a regulatory application from Teva for a contraceptive drug, the company said Monday.

FRAZER, Pa. — The Food and Drug Administration is reviewing a regulatory application from Teva for a contraceptive drug, the company said Monday.

Teva Women's Health, part of Israeli drug maker Teva Pharmaceutical Industries, announced the FDA's acceptance of its application for Quartette (levonorgestrel/ethinyl estradiol and ethinyl estradiol), which the company called the first ascending-dose, extended regimen oral contraceptive for preventing pregnancy.

June 29, 2011

Lilly: Axiron improves hypogonadism symptoms among men

A topical drug made by Eli Lilly restored testosterone to normal levels in men with abnormally low testosterone, according to results of a late-stage clinical trial.

INDIANAPOLIS — A topical drug made by Eli Lilly restored testosterone to normal levels in men with abnormally low testosterone, according to results of a late-stage clinical trial.

Lilly announced results of a phase-3 trial of Axiron (testosterone) topical solution, a treatment for the condition, also known as hypogonadism. Study results also showed that the drug improved symptoms associated with it.

Hypogonadism results from damage or disease of the testicles, hypothalamus or pituitary glands that inhibits production of testosterone.

June 27, 2011

Summer's Eve delivers frank message in new campaign

Feminine hygiene brand Summer's Eve recently launched a video that encourages dialogue about the female anatomy.

LYNCHBURG, Va. — Feminine hygiene brand Summer's Eve recently launched a video that encourages dialogue about the female anatomy.

The brand launched the "That's Vaginal!" video to encourage consumers to move away from euphemisms and from treating the vagina as a taboo topic, Summer's Eve said, adding that the video will be supported with a redesigned website and candid attitude.

June 1, 2011

FDA to examine possible link between drospirenone, blood clots risk

The Food and Drug Administration is investigating a possible link between a class of birth control pills and a higher risk of blood clots in the women taking them, the agency said.

SILVER SPRING, Md. — The Food and Drug Administration is investigating a possible link between a class of birth control pills and a higher risk of blood clots in the women taking them, the agency said.

March 4, 2011

Freeman adds three facial products to Feeling Beautiful line

Freeman Beauty's Feeling Beautiful line is expanding with three new products.

NEW YORK — Freeman Beauty's Feeling Beautiful line is expanding with three new products.

New to the collection are:

Feeling Beautiful kiwi and yogurt moisturizing facial cleanser. This creamy facial cleanser gently removes impurities and clears skin without drying it out. Kiwi fruit extract moisturizes and protects skin against free radicals, while the yogurt extract helps smooth skin to improve its overall texture;

December 23, 2010

FDA approves Watson oral contraceptive

The Food and Drug Administration has approved the first and only low-dose oral contraceptive to combine 0.8-mg norethindrone and 0.025-mg ethinyl estradiol in a chewable form, with four 75-mg ferrous fumarate (iron) placebo tablets, Watson Pharmaceuticals has announced.

MORRISTOWN, N.J. — The Food and Drug Administration has approved the first and only low-dose oral contraceptive to combine 0.8-mg norethindrone and 0.025-mg ethinyl estradiol in a chewable form, with four 75-mg ferrous fumarate (iron) placebo tablets, Watson Pharmaceuticals has announced.

Watson's new oral contraceptive is positioned as a novel alternative to currently available birth control pills, and the dosing combination and 24-day active hormone regimen is intended to provide users with a low level of breakthrough bleeding and short, light, predictable periods.

November 14, 2010

Zestra event addresses female sexual dysfunction

The makers of Zestra held a symposium on Oct. 28 at New York’s Penn Club...

NEW YORK — The makers of Zestra held a symposium on Oct. 28 at New York’s Penn Club to promote the over-the-counter product designed to address women’s sexual dysfunction.

October 27, 2010

Symposium addresses sexual dysfunction among women

Sexual dysfunction often is conceived as a male phenomenon, but it frequently affects women as...

NEW YORK Sexual dysfunction often is conceived as a male phenomenon, but it frequently affects women as well, and for a wide variety of reasons.

October 21, 2010

New Lo Loestrin Fe gets FDA approval

The Food and Drug Administration has approved a new contraceptive from Warner Chilcott, the drug...

ARDEE, Ireland The Food and Drug Administration has approved a new contraceptive from Warner Chilcott, the drug maker said Friday.

The company said it plans to launch Lo Loestrin Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets) early next year. The company said the contraceptive contains the lowest dosage of estrogen — 10 micrograms — of any oral contraceptive currently available in the U.S. market.

May 6, 2010

FDA approves oral contraceptive Natazia

The Food and Drug Administration has approved a new oral contraceptive made by Bayer, the...